U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Lamina lucida cleavage

MedGen UID:
867365
Concept ID:
C4021730
Finding
Synonyms: Blistering with junctional split; Junctional split; Subepidermal blistering with cleavage in the lamina lucida
 
HPO: HP:0003341

Definition

The formation of bullae (blisters) with cleavage in the lamina lucida layer of the skin. [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVLamina lucida cleavage

Conditions with this feature

Junctional epidermolysis bullosa gravis of Herlitz
MedGen UID:
36328
Concept ID:
C0079683
Disease or Syndrome
Junctional epidermolysis bullosa (JEB) is characterized by fragility of the skin and mucous membranes, manifest by blistering with little or no trauma. Blistering may be severe and granulation tissue can form on the skin around the oral and nasal cavities, fingers and toes, and internally around the upper airway. Blisters generally heal with no significant scarring. Broad classification of JEB includes JEB generalized severe and JEB generalized intermediate. In JEB generalized severe, blisters are present at birth or become apparent in the neonatal period. Congenital malformations of the urinary tract and bladder may also occur. In JEB generalized intermediate, the phenotype may be mild with blistering localized to hands, feet, knees, and elbows with or without renal or ureteral involvement. Some individuals never blister after the newborn period. Additional features shared by JEB and the other major forms of epidermolysis bullosa (EB) include congenital localized absence of skin (aplasia cutis congenita), milia, nail dystrophy, scarring alopecia, hypotrichosis, pseudosyndactyly, and other contractures.
Epidermolysis bullosa, junctional 4, intermediate
MedGen UID:
382015
Concept ID:
C2608084
Disease or Syndrome
Junctional epidermolysis bullosa with pyloric atresia
MedGen UID:
1810975
Concept ID:
C5676875
Disease or Syndrome
Epidermolysis bullosa with pyloric atresia (EB-PA) is characterized by fragility of the skin and mucous membranes, manifested by blistering with little or no trauma; congenital pyloric atresia; and ureteral and renal anomalies (dysplastic/multicystic kidney, hydronephrosis/hydroureter, ureterocele, duplicated renal collecting system, absent bladder). The course of EB-PA is usually severe and often lethal in the neonatal period. Most affected children succumb as neonates; those who survive may have severe blistering with formation of granulation tissue on the skin around the mouth, nose, fingers, and toes, and internally around the trachea. However, some affected individuals have little or no blistering later in life. Additional features shared by EB-PA and the other major forms of EB include congenital localized absence of skin (aplasia cutis congenita) affecting the extremities and/or head, milia, nail dystrophy, scarring alopecia, hypotrichosis, contractures, and dilated cardiomyopathy.
Epidermolysis bullosa, junctional 2B, severe
MedGen UID:
1805467
Concept ID:
C5676937
Disease or Syndrome
Severe junctional epidermolysis bullosa 2B (JEB2B) is an autosomal recessive skin blistering disorder characterized by extreme fragility of the skin and epithelia of various extracutaneous tissues. Skin blisters and erosions are present at birth. The plane of skin cleavage is through the lamina lucida of the cutaneous basement membrane zone. Oral mucosal blistering and laryngeal and esophageal mucosal involvement can occur. Patients usually die before 1 year of age (summary by Has et al., 2020). For a discussion of genetic heterogeneity of the subtypes of JEB, see JEB1A (226650). Reviews Has et al. (2020) reviewed the clinical and genetic aspects, genotype-phenotype correlations, disease-modifying factors, and natural history of epidermolysis bullosa.
Epidermolysis bullosa, junctional 3A, intermediate
MedGen UID:
1812940
Concept ID:
C5676938
Disease or Syndrome
Intermediate junctional epidermolysis bullosa 3A (JEB3A) is an autosomal recessive blistering disease of skin and mucous membranes. Blistering is less severe than in severe JEB (see 226700). The plane of skin cleavage is through the lamina lucida of the cutaneous basement membrane zone. Nail and dental abnormalities occur. Blistering does not affect the life span of affected individuals (summary by Has et al., 2020). For a discussion of genetic heterogeneity of the subtypes of JEB, see JEB1A (226650). Reviews Has et al. (2020) reviewed the clinical and genetic aspects, genotype-phenotype correlations, disease-modifying factors, and natural history of epidermolysis bullosa.
Epidermolysis bullosa, junctional 3B, severe
MedGen UID:
1807897
Concept ID:
C5676939
Disease or Syndrome
Severe junctional epidermolysis bullosa 3B (JEB3B) is an autosomal recessive skin blistering disorder characterized by extreme fragility of the skin and epithelia of various extracutaneous tissues. Skin blisters and erosions are present at birth. The plane of skin cleavage is through the lamina lucida of the cutaneous basement membrane zone. Patients die in infancy to early adulthood (summary by Has et al., 2020). For a discussion of genetic heterogeneity of the subtypes of JEB, see JEB1A (226650). Reviews Has et al. (2020) reviewed the clinical and genetic aspects, genotype-phenotype correlations, disease-modifying factors, and natural history of epidermolysis bullosa.
Epidermolysis bullosa, junctional 5A, intermediate
MedGen UID:
1811851
Concept ID:
C5676956
Disease or Syndrome
Intermediate junctional epidermolysis bullosa 5A (JEB5A) is an autosomal recessive blistering disease of skin and mucous membranes. Blistering is less severe than in severe JEB (see 226700). The plane of skin cleavage is through the lamina lucida of the cutaneous basement membrane zone. Nails may be dystrophic and dental enamel defects are present. Blistering does not affect the life span of affected individuals (summary by Has et al., 2020). For a discussion of genetic heterogeneity of the subtypes of JEB, see JEB1A (226650). Reviews Has et al. (2020) reviewed the clinical and genetic aspects, genotype-phenotype correlations, disease-modifying factors, and natural history of epidermolysis bullosa.
Epidermolysis bullosa, junctional 6, with pyloric atresia
MedGen UID:
1803348
Concept ID:
C5676957
Disease or Syndrome
Epidermolysis bullosa with pyloric atresia (EB-PA) is characterized by fragility of the skin and mucous membranes, manifested by blistering with little or no trauma; congenital pyloric atresia; and ureteral and renal anomalies (dysplastic/multicystic kidney, hydronephrosis/hydroureter, ureterocele, duplicated renal collecting system, absent bladder). The course of EB-PA is usually severe and often lethal in the neonatal period. Most affected children succumb as neonates; those who survive may have severe blistering with formation of granulation tissue on the skin around the mouth, nose, fingers, and toes, and internally around the trachea. However, some affected individuals have little or no blistering later in life. Additional features shared by EB-PA and the other major forms of EB include congenital localized absence of skin (aplasia cutis congenita) affecting the extremities and/or head, milia, nail dystrophy, scarring alopecia, hypotrichosis, contractures, and dilated cardiomyopathy.

Recent clinical studies

Etiology

Mariath LM, Santin JT, Schuler-Faccini L, Kiszewski AE
An Bras Dermatol 2020 Sep-Oct;95(5):551-569. Epub 2020 Jul 8 doi: 10.1016/j.abd.2020.05.001. PMID: 32732072Free PMC Article
Nishie W
Acta Derm Venereol 2020 Feb 12;100(5):adv00054. doi: 10.2340/00015555-3399. PMID: 32039455Free PMC Article
Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, Vlodavsky I
FEBS J 2010 Oct;277(19):3890-903. Epub 2010 Aug 31 doi: 10.1111/j.1742-4658.2010.07799.x. PMID: 20840586Free PMC Article
Kao CH, Chen SJ, Hwang B, Yang AH, Hsu CY, Huang CH
J Chin Med Assoc 2006 Oct;69(10):503-6. doi: 10.1016/S1726-4901(09)70318-1. PMID: 17098678
Cooper TW, Bauer EA
Pediatr Dermatol 1984 Jan;1(3):181-8. doi: 10.1111/j.1525-1470.1984.tb01113.x. PMID: 6387664

Diagnosis

Mariath LM, Santin JT, Schuler-Faccini L, Kiszewski AE
An Bras Dermatol 2020 Sep-Oct;95(5):551-569. Epub 2020 Jul 8 doi: 10.1016/j.abd.2020.05.001. PMID: 32732072Free PMC Article
Genovese F, Karsdal MA
Expert Rev Proteomics 2016;13(2):213-25. doi: 10.1586/14789450.2016.1134327. PMID: 26689914
Shinkuma S, McMillan JR, Shimizu H
Clin Dermatol 2011 Jul-Aug;29(4):412-9. doi: 10.1016/j.clindermatol.2011.01.010. PMID: 21679868
Rodrigues EB, Meyer CH, Mennel S, Farah ME
Retina 2007 Sep;27(7):958-70. doi: 10.1097/01.iae.0000253051.01194.ab. PMID: 17891024
Kao CH, Chen SJ, Hwang B, Yang AH, Hsu CY, Huang CH
J Chin Med Assoc 2006 Oct;69(10):503-6. doi: 10.1016/S1726-4901(09)70318-1. PMID: 17098678

Therapy

de Nicolas-Ruanes B, Ballester-Martinez A, Garcia-Mouronte E, Berna-Rico E, Azcarraga-Llobet C, Fernandez-Guarino M
Int J Mol Sci 2023 Nov 26;24(23) doi: 10.3390/ijms242316786. PMID: 38069109Free PMC Article
Uhlin F, Szpirt W, Kronbichler A, Bruchfeld A, Soveri I, Rostaing L, Daugas E, Lionet A, Kamar N, Rafat C, Mysliveček M, Tesař V, Fernström A, Kjellman C, Elfving C, McAdoo S, Mölne J, Bajema I, Sonesson E, Segelmark M
J Am Soc Nephrol 2022 Apr;33(4):829-838. Epub 2022 Mar 8 doi: 10.1681/ASN.2021111460. PMID: 35260419Free PMC Article
Turner CT, Zeglinski MR, Richardson KC, Santacruz S, Hiroyasu S, Wang C, Zhao H, Shen Y, Sehmi R, Lima H, Gauvreau GM, Granville DJ
J Invest Dermatol 2021 Jan;141(1):36-47. Epub 2020 Jun 3 doi: 10.1016/j.jid.2020.05.095. PMID: 32504614
Békássy ZD, Kristoffersson AC, Rebetz J, Tati R, Olin AI, Karpman D
Kidney Int 2018 Oct;94(4):689-700. Epub 2018 Jun 5 doi: 10.1016/j.kint.2018.04.004. PMID: 29884545
Rundhaug JE
J Cell Mol Med 2005 Apr-Jun;9(2):267-85. doi: 10.1111/j.1582-4934.2005.tb00355.x. PMID: 15963249Free PMC Article

Prognosis

Uhlin F, Szpirt W, Kronbichler A, Bruchfeld A, Soveri I, Rostaing L, Daugas E, Lionet A, Kamar N, Rafat C, Mysliveček M, Tesař V, Fernström A, Kjellman C, Elfving C, McAdoo S, Mölne J, Bajema I, Sonesson E, Segelmark M
J Am Soc Nephrol 2022 Apr;33(4):829-838. Epub 2022 Mar 8 doi: 10.1681/ASN.2021111460. PMID: 35260419Free PMC Article
Nishie W
Acta Derm Venereol 2020 Feb 12;100(5):adv00054. doi: 10.2340/00015555-3399. PMID: 32039455Free PMC Article
Young KZ, Lee SJ, Zhang X, Cartee NMP, Torres M, Keep SG, Gabbireddy SR, Fontana JL, Qi L, Wang MM
J Biol Chem 2020 Feb 14;295(7):1960-1972. Epub 2020 Jan 4 doi: 10.1074/jbc.RA119.007724. PMID: 31901894Free PMC Article
Genovese F, Karsdal MA
Expert Rev Proteomics 2016;13(2):213-25. doi: 10.1586/14789450.2016.1134327. PMID: 26689914
Yoshizaki T, Sato H, Furukawa M
Oncol Rep 2002 May-Jun;9(3):607-11. PMID: 11956636

Clinical prediction guides

Tang GQ, Tang Y, Dhamnaskar K, Hoarty MD, Vyasamneni R, Vadysirisack DD, Ma Z, Zhu N, Wang JG, Bu C, Cong B, Palmer E, Duda PW, Sayegh C, Ricardo A
Front Immunol 2023;14:1213920. Epub 2023 Aug 9 doi: 10.3389/fimmu.2023.1213920. PMID: 37622108Free PMC Article
Young KZ, Lee SJ, Zhang X, Cartee NMP, Torres M, Keep SG, Gabbireddy SR, Fontana JL, Qi L, Wang MM
J Biol Chem 2020 Feb 14;295(7):1960-1972. Epub 2020 Jan 4 doi: 10.1074/jbc.RA119.007724. PMID: 31901894Free PMC Article
Schlötzer-Schrehardt U, Bachmann BO, Laaser K, Cursiefen C, Kruse FE
Ophthalmology 2011 Oct;118(10):1950-7. Epub 2011 Jun 25 doi: 10.1016/j.ophtha.2011.03.025. PMID: 21705086
Shinkuma S, McMillan JR, Shimizu H
Clin Dermatol 2011 Jul-Aug;29(4):412-9. doi: 10.1016/j.clindermatol.2011.01.010. PMID: 21679868
Abdelsalam A, Del Priore L, Zarbin MA
Surv Ophthalmol 1999 Jul-Aug;44(1):1-29. doi: 10.1016/s0039-6257(99)00072-7. PMID: 10466585

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...